1 / 8

Carcinoembryonic Antigen (CEA) Market to reach $2.7bn by 2023

Get more details @ http://bit.ly/2kkzZLr <br>Companies operating in carcinoembryonic antigen market includes Abbott Diagnostics, Roche Diagnostics, Quest Diagnostics and GenWay Biotech. Companies operating in this industry are focusing on strategies such as mergers and acquisitions to maintain leadership position.

jueekate
Télécharger la présentation

Carcinoembryonic Antigen (CEA) Market to reach $2.7bn by 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Carcinoembryonic Antigen (CEA) Market share to grow at 6% CAGR from 2016 to 2023: Global Market Insights Inc. Fuel Cell Market size worth $25.5bn by 2024

  2. Key Insights from Carcinoembryonic Antigen Market : • Global Carcinoembryonic Antigen Market is set to register profitable growth in the near future and surpass USD 2.8 billion by 2023. • This growth is attributed to factors including consistent technology advancements, development of novel biomarkers and growing prevalence of cancer. • Growing demand for minimally invasive diagnostics procedures is projected to contribute a significant part in shaping market growth. Increasing geriatric population is another key factor to intensify the Carcinoembryonic Antigen market growth.  • The development of novel combination biomarkers and initiatives by the government concerning improved diagnostic rates are likely to open growth avenues for CEA market.

  3. Continued... • North America, hinged on the U.S. Carcinoembryonic Antigen market size, is predicted to lead the segment with estimations of USD 800 million in 2016. • Growing awareness about detecting cancer at an early stage and improved health care services for cancer therapeutics are anticipated to propel growth. • Asia-Pacific region driven by India and China is targeted to foresee growing prevalence of cancer owing to changes in lifestyle and aging population in the area. The growth is mainly attributed to improved treatment facilities and high disposable income. • Colorectal cancer tops the application segment and is expected to foresee growth over the forecast period. Breast cancer segment is likely to be the most lucrative with estimations of over USD 460 million at over 7% CAGR during the projected time frame.

  4. Germany Carcinoembryonic Antigen (CEA) Market size, by application, 2012-2023 (USD Million)

  5. Browse Full Market Research Report On Carcinoembryonic Antigen Market @ http://bit.ly/2pqae1Q Request for a Sample of this Research Report @ https://www.gminsights.com/request-sample/detail/427https://www.gminsights.com/request-sample/detail/49

  6. Table of Content: Chapter 1. Methodology and Scope 1.1. Research Methodology 1.1.1. Initial data exploration 1.1.2. Statistical model and forecast 1.1.3. Industry insights and validation 1.1.4. Research scope & assumptions 1.2. Data Sources 1.2.1. Primary Sources 1.2.2. Secondary Sources Chapter 2. Executive Summary 2.1. Carcinoembryonic antigen industry 3600 synopsis, 2012 - 2023 2.1.1. Business trends 2.1.2. Application trends 2.1.3. Regional trends

  7. Chapter 3. Carcinoembryonic antigen Industry Insights 3.1. Industry segmentation 3.2. Industry size and forecast, 2012 - 2023 3.3. Industry impact forces 3.3.1. Growth drivers 3.3.1.1. Growing elderly population base 3.3.1.2. Minimally invasive diagnostic procedure demand 3.3.1.3. Increasing cancer prevalence 3.3.1.4. Combination biomarker adoption surge 3.3.1.5. Healthcare expenditure trends 3.3.1.6. CEA usage in cancer 3.3.2. Industry pitfalls & challenges 3.3.2.1. Complex regulatory landscape 3.3.2.2. Ineffectiveness in detecting cancer at early stages 3.4. Growth potential benchmarking 3.5. Company market share analysis, 2015 3.5.1. Strategy dashboard 3.6. Porter’s analysis 3.7. PESTEL analysis

  8. Stay In Touch Website: www.gminsights.com Social Media:

More Related